Literature DB >> 1284120

Generation of monoclonal antibodies against a human T cell receptor beta chain expressed in transgenic mice.

J L Viney1, H M Prosser, C R Hewitt, J R Lamb, M J Owen.   

Abstract

The generation of a panel of monoclonal antibodies specific for different variable (V) regions of human T cell receptors will be of great importance in the study of T cell-mediated diseases. However, relatively few such reagents exist, due in part to the poor immunogenicity of TcRs on the surface of human T cells. We have employed a strategy in which T cells from a transgenic mouse line expressing a human V beta 3 C beta 1 TcR were used to immunise syngeneic conventional mice to generate two monoclonal antibodies specific for human T cell receptors. Binding of antibody JOVI.3, which stained approximately 5% of human peripheral blood CD3 positive T cells, correlated with the expression of the human TcR V beta 3 gene segment. Antibody JOVI.1 recognised a determinant on the majority of TcRs, staining 50-75% of peripheral blood T cells and T cell lines expressing different V beta regions. Some TcRs, however, failed to react with this antibody. Both antibodies immunoprecipitated detergent-solubilised TcR molecules and were capable of inducing proliferation of peripheral blood T cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1284120     DOI: 10.1089/hyb.1992.11.701

Source DB:  PubMed          Journal:  Hybridoma        ISSN: 0272-457X


  7 in total

1.  CD31, a Valuable Marker to Identify Early and Late Stages of T Cell Differentiation in the Human Thymus.

Authors:  Marc Douaisi; Rachel S Resop; Maho Nagasawa; Joshua Craft; Beth D Jamieson; Bianca Blom; Christel H Uittenbogaart
Journal:  J Immunol       Date:  2017-02-03       Impact factor: 5.422

2.  Reactivity of mouse T-cell hybridomas expressing human Vbeta gene segments with staphylococcal and streptococcal superantigens.

Authors:  B Fleischer; A Necker; C Leget; B Malissen; F Romagne
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

3.  Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies.

Authors:  Paul M Maciocia; Patrycja A Wawrzyniecka; Brian Philip; Ida Ricciardelli; Ayse U Akarca; Shimobi C Onuoha; Mateusz Legut; David K Cole; Andrew K Sewell; Giuseppe Gritti; Joan Somja; Miguel A Piris; Karl S Peggs; David C Linch; Teresa Marafioti; Martin A Pule
Journal:  Nat Med       Date:  2017-11-13       Impact factor: 53.440

4.  Large granular lymphocyte expansions in patients with Felty's syndrome: analysis using anti-T cell receptor V beta-specific monoclonal antibodies.

Authors:  S J Bowman; M Bhavnani; G C Geddes; V Corrigall; A W Boylston; G S Panayi; J S Lanchbury
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

5.  In vitro translation and assembly of a complete T cell receptor-CD3 complex.

Authors:  J B Huppa; H L Ploegh
Journal:  J Exp Med       Date:  1997-08-04       Impact factor: 14.307

Review 6.  Emerging Role of T-cell Receptor Constant β Chain-1 (TRBC1) Expression in the Flow Cytometric Diagnosis of T-cell Malignancies.

Authors:  Pedro Horna; Min Shi; Horatiu Olteanu; Ulrika Johansson
Journal:  Int J Mol Sci       Date:  2021-02-12       Impact factor: 5.923

7.  Computational discovery of binding mode of anti-TRBC1 antibody and predicted key amino acids of TRBC1.

Authors:  Jirakrit Saetang; Surasak Sangkhathat; Nawaphat Jangphattananont; Wannakorn Khopanlert; Jakrawadee Julamanee; Varomyalin Tipmanee
Journal:  Sci Rep       Date:  2022-02-02       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.